Fast-Dispersing Imidazole Dosage for Pre-Gastric Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Substituted imidazole derivatives used for treating cognitive disorders decompose quickly in the gastrointestinal area when administered orally, leading to reduced effectiveness and adverse reactions when used in conventional formulations.
Innovation Solution
Formulating the compounds into fast-dispersing solid dosage forms that promote pre-gastric absorption through the oral mucosal membrane, avoiding stomach decomposition and enhancing bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional oral administration is used, then the compound can be administered easily, but the compound decomposes quickly in the gastrointestinal area reducing effectiveness
Solution Approach 1:
The patent applies preliminary action by formulating the compound into a fast-dispersing dosage form that dissolves rapidly in the oral cavity before the compound can be degraded by gastrointestinal enzymes. This pre-dissolution step protects the compound from degradation while maintaining ease of oral administration.
Solution Approach 2:
The patent uses an intermediary approach by introducing a fast-dispersing formulation system that acts as a mediator between the compound and the gastrointestinal environment. This formulation system protects the compound from direct contact with degrading enzymes while still allowing absorption through the oral mucosal membrane.
2Reliability
If buccal spray is used, then bioavailability is increased, but transient adverse reactions such as white spots and numbness occur at the application site
Solution Approach 1:
The patent applies parameter changes by modifying the physical state and delivery parameters of the compound. Instead of using a spray formulation that contacts the buccal mucosa directly, the invention uses a fast-dispersing solid dosage form that dissolves in saliva, changing the delivery parameters to avoid local irritation while maintaining high bioavailability through pre-gastric absorption.
3Reliability
If fast-dispersing dosage form is used, then pre-gastric absorption is promoted, but the formulation complexity increases
Solution Approach 1:
The patent applies phase transitions by utilizing the transition from solid to dissolved state in the fast-dispersing dosage form. The compound is formulated in a solid matrix that rapidly dissolves in the aqueous environment of the oral cavity, exploiting the phase transition to achieve rapid dispersion and absorption without requiring complex delivery devices or formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fast-dispersing dosage forms ensure rapid absorption and improved bioavailability of the active ingredient, reducing adverse reactions and maintaining effectiveness, with disintegration times of less than 8 seconds, and stability over four weeks of storage.
Implementation Method 1
promote pre-gastric absorption of the active ingredient
Data Source
AI summary
Improved formulations containing substituted imidazole derivatives of the general formula 1, formula (I) wherein Y is —CH2— or —CO—, R1 is H, halo or hydroxy, R2 is H or halo, and R3 is H or lower alkyl (e.g. C1 to C4 alkyl, preferably C1 or C2 alkyl), or a pharmaceutically acceptable salt, such as an acid addition salt, e.g. the hydrochloride, of a compound of the general formula (I), are in solid fast-dispersing dosage form suitable for pre-gastric absorption.